Donor vaccine may shield transplant patients from dangerous virus
NCT ID NCT03560752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can prevent the virus from causing problems in blood cancer patients after a transplant. About 34 donor-recipient pairs are taking part. The vaccine is given to the donor before stem cell collection, aiming to boost the recipient's immunity and reduce CMV-related complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE CML, BCR-ABL1 POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a modified interferon rein in early myelofibrosis?
- Can pressurized oxygen boost cord blood transplants?
- Could a targeted drug boost stem cell transplant success in lymphoma?